首轨生物治疗
TRAX
34.46
-1.58
-4.38%
首轨生物治疗
US · TRAX
#3189 按市值排名
上市于 2026
34.46
-1.58
-4.38%
实时 - 追踪5344个代码 - 心跳于242秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了5家。
- 机构持股总比例下降了3.1个百分点。
机构持股
- 机构持股比例
- 102.96% -3.13pp
- 机构数量
- 182 -5
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund45.03%
Hedge Fund38.82%
VC/PE Fund10.58%
Public Company7.78%
Individual/Insider1.84%
Private Company0.26%
Sovereign Wealth Fund0.19%
Government Pension Fund0.17%
Insurance Company0.13%
主要股东 截至 2026-06-30
EcoR1 Capital, LLC
8.88% · 3.17M 股
TCG Crossover Management, LLC
8.10% · 2.90M 股
Sirenia Capital Management LP
6.98% · 2.50M 股
FMR
5.75% · 2.05M 股
Affinity Asset Advisors, LLC
5.69% · 2.03M 股
BlackRock
5.50% · 1.96M 股
Vanguard Capital Management, LLC
4.60% · 1.64M 股
Trails Edge Capital Partners, LP
4.24% · 1.51M 股
State Street Global Advisors
4.23% · 1.51M 股
Janus Henderson Group plc
3.05% · 1.09M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 45次买入 · 3次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Daniel Faga | Chief Executive Officer | 1.39% |
| Paul Lizzul | Chief Medical Officer | 0.12% |
| John Schmid | Director | 0.11% |
| Rita Jain | Director | 0.05% |
| John Orwin | Director | 0.05% |
| Magda Marquet | Director | 0.04% |
| J. Ware | Director | 0.04% |
| Dennis Fenton | Director | 0.03% |
| Ajim Tamboli | Chief Financial Officer | -- |
| AnaptysBio, Inc. | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-14 | John Orwin | Director | Derivative Exercise and Retained | +1,300 | -- |
| 2026-09-01 | J. Ware | Director | Derivative Exercise and Sale | -39,265 | $5.74–44.78 |
| 2026-08-14 | Paul Lizzul | Chief Medical Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-08-14 | Daniel Faga | Chief Executive Officer | Other Derivative Acquisition | +193,575 | -- |
| 2026-08-14 | Benjamin Stone | Chief Business Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-08-01 | Paul Lizzul | Chief Medical Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-08-01 | Daniel Faga | Chief Executive Officer | Other Derivative Acquisition | +193,576 | -- |
| 2026-08-01 | Benjamin Stone | Chief Business Officer | Other Derivative Acquisition | +60,492 | -- |
| 2026-06-14 | John Orwin | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | John Schmid | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | Dennis Fenton | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | Magda Marquet | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | J. Ware | Director | Derivative Exercise and Retained | +6,030 | -- |
| 2026-06-14 | Rita Jain | Director | Derivative Exercise and Retained | +7,330 | -- |
| 2026-05-11 | John Orwin | Director | Other Derivative Acquisition | +2,500 | -- |
| 2026-05-11 | John Orwin | Director | Other Derivative Acquisition | +7,000 | $17.81 |
| 2026-05-11 | John Schmid | Director | Other Derivative Acquisition | +2,500 | -- |
| 2026-05-11 | John Schmid | Director | Other Derivative Acquisition | +7,000 | $17.81 |
| 2026-05-11 | Dennis Fenton | Director | Other Derivative Acquisition | +2,500 | -- |
| 2026-05-11 | Dennis Fenton | Director | Other Derivative Acquisition | +7,000 | $17.81 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
首轨生物治疗 讨论区 0 条评论